Written by Kevin Liu
Spoon Feed
Inebilizumab reduced the risk of flares of IgG4-related disease (IgG4-RD) and increased the likelihood of flare-free remission at 1 year in a small phase III clinical trial that warrants a longer, larger study to establish its safety.
Synopsis
This phase 3, multicenter, double-blind, randomized trial compared inebilizumab and placebo in 135 adults with IgG4-RD across 22 countries. Participants received glucocorticoids for 3–8 weeks, tapered to 20 mg prior to randomization and reduced by 5 mg every two weeks until discontinuation at 8 weeks after randomization. Concomitant immunosuppressants or glucocorticoids were prohibited. Inebilizumab significantly reduced flare risk (10% vs. 60%, hazard ratio 0.13; P<0.001) and annualized flare rates (rate ratio 0.14; P<0.001). Secondary outcomes included higher treatment- and glucocorticoid-free remission rates at one year. Despite increased grade 3 or serious adverse events, mainly lymphopenia and UTI, the study supports CD19-targeted B-cell depletion as an effective therapy. Long-term safety remains uncertain. (ChatGPT-assisted)
Imebilizumab, good for some, likely expensive for all
IgG4-RD is an orphan disease lacking disease-specific treatment. The MITIGATE trial introduces inebilizumab, a CD19-targeted B-cell depletion therapy, showing significant reductions in flare risk, annualized flare rates, and glucocorticoid-free complete remission at week 52 with biannual infusions. However, the therapy presents higher risks of lymphopenia and UTI compared to glucocorticoids. A concern is that the trial compared inebilizumab to patients receiving no treatment after initial glucocorticoid tapering. Historically, 11% of IgG4-RD patients required no ongoing treatment, while 74% relied on maintenance glucocorticoids. Additionally, rituximab, used in small observational studies (n < 30), demonstrated comparable efficacy. Despite long-standing glucocorticoid use and promising outcomes with rituximab, no FDA-approved therapies exist due to insufficient high-quality evidence from clinical trials. Inebilizumab may become the first FDA-approved drug for IgG4-RD, but will it outperform glucocorticoids or rituximab? I am doubtful, but if it receives approval, it may be drug treatment that insurance will cover. In discussing options with patients, I emphasize trade-offs and cost. Glucocorticoids are cheap, with lower risks of UTI and opportunistic infections, but they cause weight gain and diabetes. Inebilizumab will be expensive and increases risk of lymphopenia and infections but reduces flare rates. The decision depends on individual patient priorities, balancing efficacy, risks, and financial burden. I would be hesitant to recommend Imebilizumab first line for now.
Editor’s note: For those of us who have never heard of it, IgG4-related disease is a chronic, relapsing, multi-organ fibro-inflammatory autoimmune condition with infiltration of almost any organ by IgG4+ plasma cells, causing enlargement of the lacrimal glands, salivary glands, autoimmune pancreatitis, retroperitoneal fibrosis, tubulointerstitial nephritis, and other manifestations. ~Clay Smith
Source
MITIGATE Trial Investigators. Inebilizumab for Treatment of IgG4-Related Disease. N Engl J Med. 2024 Nov 14. doi: 10.1056/NEJMoa2409712. Epub ahead of print. PMID: 39541094
